OKUR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Onkure Therapeutics Inc (OKUR) is not a strong buy for a beginner, long-term investor at this time. Despite bullish technical indicators, the company's poor financial performance, lack of positive news catalysts, and neutral trading sentiment suggest that the stock does not currently present a compelling long-term investment opportunity.
The technical indicators for OKUR are bullish, with a positively expanding MACD histogram (0.0517), an overbought RSI (80.164), and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 4.586), which may limit immediate upside potential.
The stock exhibits bullish technical indicators, and the MACD and moving averages suggest upward momentum.
Analysts have also lowered the price target from $34 to $27 due to an anticipated equity raise in Q
Additionally, there is no recent news or significant trading activity from insiders, hedge funds, or Congress.
In Q4 2025, Onkure Therapeutics reported no revenue growth (0.00% YoY), a net income decline to -$13,503,000 (-61.63% YoY), and a sharp drop in EPS to -0.99 (-89.42% YoY). Gross margin remains at 0.
H.C. Wainwright maintains a Buy rating but has lowered the price target to $27 from $34, factoring in an equity raise in Q2.
